BGLC.NASDAQBionexus Gene Lab CORP
10-Q: BioNexus Gene Lab Corp. Reports Q1 2025 Results, Navigates Nasdaq Compliance, and Expands into Digital Assets
Sentiment:
Quarterly Report (Form 10-Q)
BioNexus Gene Lab Corp. announces its Q1 2025 financial results, highlighting a strategic shift towards digital assets and addressing Nasdaq compliance while experiencing a revenue decrease.
Capital raiseThe Company is actively exploring additional capital-raising mechanisms.These may include at-the-market offerings, private placements, or strategic financing arrangements subject to Nasdaq and SEC compliance.
Worse than expectedThe company's net loss increased significantly compared to the same period last year.Revenue decreased, indicating a slowdown in business activity.Operating expenses increased, offsetting any potential gains from cost of revenue reductions.
Summary
- BioNexus Gene Lab Corp. reported a net loss of $623,327 for the quarter ended March 31, 2025, compared to a net loss of $103,757 for the same period in 2024.
- Revenue decreased by 10.3% to $2,137,075, with Chemrex contributing the majority at $2,134,007, while MRNA Scientific generated $3,068.
- The company's operating expenses increased by 63.3% to $1,053,331, driven by higher sales and marketing, general and administrative, and research and development expenses.
- As of March 31, 2025, BioNexus Gene Lab Corp. had cash and cash equivalents of $3.6 million and total liquidity exceeding $6 million.
- The company successfully regained compliance with Nasdaq listing rules after implementing a 1-for-10 reverse stock split.
- BioNexus Gene Lab Corp. is expanding into digital healthcare and decentralized asset infrastructure, including an Ethereum-focused treasury strategy.
- The company is exploring additional capital-raising mechanisms to support growth initiatives.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company has a strong liquidity position and is pursuing innovative strategies, it also faces significant challenges, including increased losses, decreased revenue, and internal control deficiencies. The successful Nasdaq compliance is a positive, but the overall outlook is uncertain.
Positives
- The company has a strong liquidity position with $3.6 million in cash and cash equivalents and over $6 million in total liquidity.
- BioNexus Gene Lab Corp. has a clean capital structure with minimal outstanding debt and no preferred stock or convertible debt.
- The company successfully regained compliance with Nasdaq listing rules.
- BioNexus Gene Lab Corp. is expanding into digital healthcare and decentralized asset infrastructure, including an Ethereum-focused treasury strategy.
- The company is enhancing its internal controls, particularly at the Chemrex subsidiary.
Negatives
- The company reported a significantly increased net loss of $623,327 for Q1 2025 compared to $103,757 for Q1 2024.
- Revenue decreased by 10.3% to $2,137,075.
- Operating expenses increased by 63.3% to $1,053,331.
- The company identified a significant deficiency in internal control over financial reporting at the Chemrex subsidiary.
- MRNA Scientific's revenue decreased slightly due to fewer client referrals and the unavailability of a key RNA machine.
Risks
- The company's ability to improve profitability and secure external financing is crucial for its ability to continue as a going concern.
- Fluctuations in foreign exchange rates could impact the company's financial results.
- The company faces risks associated with the implementation of its Ethereum-focused treasury strategy, including regulatory uncertainty and market volatility.
- The company's expansion into new markets and technologies may face challenges and require significant investment.
- The company's reliance on a few major suppliers could pose a risk to its supply chain.
Future Outlook
The company intends to capitalize on its clean balance sheet and low compliance cost profile to pursue selective mergers, acquisitions, and joint ventures that align with its long-term strategy, including investments in digital healthcare, sustainable materials, and blockchain-based treasury solutions. The company is also exploring additional capital-raising mechanisms.
Management Comments
- Our leadership team remains fully committed and confident in maintaining robust compliance with Nasdaq listing standards.
- We view compliance as fundamental to our growth strategy and market credibility.
- Our proactive compliance approach, prudent capital market strategies, and transparent shareholder communication reflect management's dedication to safeguarding shareholder value and company reputation.
Industry Context
The company's expansion into digital healthcare and blockchain-based treasury solutions reflects a broader trend of companies exploring new technologies to enhance capital efficiency and drive innovation. The company's focus on early disease detection aligns with the growing demand for preventative healthcare solutions.
Comparison to Industry Standards
- It is difficult to compare BGLC to industry standards due to its unique combination of business activities.
- Chemrex's performance can be compared to other industrial chemical wholesalers in the ASEAN region, but specific benchmarks are not provided in the document.
- MRNA Scientific's genomic screening services can be compared to other diagnostic testing companies, but specific market share or growth rate data is not available.
- The company's adoption of an Ethereum-focused treasury strategy is relatively novel, making direct comparisons to other companies challenging.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Independent Director | NA | Jook Yuen Low | November 5, 2024 | Appointment to the Board |
| Secretary | NA | Su-Leng Tan Lee | November 5, 2024 | Re-appointment |
| President | NA | Su-Leng Tan Lee | November 5, 2024 | Appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Controls Enhancement | The Company focused on enhancing its internal control environment and improving governance procedures within its Chemrex subsidiary. | During and subsequent to the reporting period ending March 31, 2025 | The Company is addressing these matters through comprehensive oversight, led by the audit committee, to ensure transparency, accuracy, and compliance in all reported information. |
Legal Proceedings
- There are presently no pending legal proceedings to which the Company or any of its property is subject.
Related Party Transactions
- The company had revenue from related parties of $16,070 for the period ended March 31, 2025, and $34,086 for the period ended March 31, 2024.
- The company had rental expenses to a related party of $1,044 for the period ended March 31, 2025, and $nil for the period ended March 31, 2024.
- During the three months ended March 31, 2025, the Company had net cash of $(860) used in financing activities due to a loan repayment of $860 to a director.
Stakeholder Impact
- Shareholders: The company's financial performance and strategic decisions will impact shareholder value.
- Employees: The company's expansion and internal control enhancements may affect employee roles and responsibilities.
- Customers: The company's product and service offerings, particularly in healthcare diagnostics and industrial chemicals, will impact customers.
- Suppliers: The company's relationships with major suppliers are important for its supply chain.
- Creditors: The company's financial stability and ability to generate cash flow will impact its creditworthiness.
Next Steps
- Complete the remediation plan to address the identified deficiency in internal control over financial reporting at the Chemrex subsidiary.
- Continue to pursue strategic mergers, acquisitions, and joint ventures that align with the company's long-term strategy.
- Implement and refine the Ethereum-focused treasury strategy.
- Monitor and manage the risks associated with the company's expansion into new markets and technologies.
- Explore and secure additional capital-raising mechanisms to support growth initiatives.
Key Dates
| Date | Description |
|---|---|
| May 12, 2017 | BioNexus Gene Lab Corp. was incorporated in the State of Wyoming. |
| August 23, 2017 | The Company acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd. |
| December 31, 2020 | The Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. |
| June 5, 2023 | The Company filed an Article of Amendment to the Articles of Incorporation with the Wyoming Secretary of State to modify the ratio of the Reverse Stock Split from one-for-ten (10) to one-for-twelve (12). |
| July 20, 2023 | The Company entered into an underwriting agreement with Network 1 Financial Securities, Inc. |
| July 24, 2023 | The Underwriter fully exercised the Over-Allotment Option. |
| October 4, 2024 | The 2024 Annual Meeting of Shareholders of BioNexus Gene Lab Corp. was held. |
| February 11, 2025 | The Company filed with the Wyoming Secretary of State Articles of Amendment to its Articles of Incorporation. |
| March 5, 2025 | The Company issued a press release announcing that its Board of Directors had formally approved a new treasury strategy focused exclusively on Ethereum (ETH) as a strategic treasury asset. |
| March 7, 2025 | The Company issued a press release announcing a strategic partnership with ML Tech to optimize its Ethereum-based growth strategies. |
| March 19, 2025 | The Company held a Special Meeting of Shareholders. |
| April 1, 2025 | The Company filed its Articles of Amendment with the Wyoming Secretary of State to effect a one for ten (1 for 10) reverse stock split of its issued and outstanding common stock. |
| April 7, 2025 | At 12:01 a.m. Eastern Time on April 7, 2025, the Company effected a reverse stock split and the Company's common stock will began trading on a split-adjusted basis on The Nasdaq Capital Market under the existing ticker symbol BGLC on that same day. |
| April 30, 2025 | The Company received a formal notice from the Nasdaq Hearings Panel (the Panel) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. |
| May 15, 2025 | Date of report filing. |
Keywords
BioNexus Gene Lab Corp, financial results, Nasdaq compliance, Ethereum, digital assets, reverse stock split, internal controls, Chemrex, MRNA Scientific, liquidity, revenue, net loss
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.